Billings Clinic

Running trials

• Recruiting

  Diagnosing Epilepsy To EffeCT Change

  NCT07110337· Source

• Recruiting

  Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up

  NCT07110454· Source

• Recruiting

  Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  NCT07214779· Phase 3· Source

• Recruiting

  A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators

  NCT06504589· Source

• Active, not recruiting

  Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

  NCT06297603· Phase 3· Source

• Recruiting

  SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

  NCT05303519· Phase 3· Source

• Recruiting

  Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study

  NCT05548283· Phase 4· Source

• Active, not recruiting

  A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

  NCT05444257· Phase 3· Source

• Active, not recruiting

  A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

  NCT05556512· Phase 3· Source

• Active, not recruiting

  CHAMPION-AF Clinical Trial

  NCT04394546· Source

• Active, not recruiting

  Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

  NCT03650114· Phase 3· Source

• Active, not recruiting

  A Trial of Vigil for Participants With Ovarian Cancer

  NCT02346747· Phase 2· Source

• Active, not recruiting

  A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer

  NCT02107703· Phase 3· Source

• Active, not recruiting

  Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

  NCT00430183· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Cystic fibrosis2 recruiting
• Epilepsy2 recruiting
• Glioblastoma1 recruiting
• Ovarian cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF)

  NCT06506773· Source

• Completed

  A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone

  NCT05971940· Phase 3· Source

• Completed

  A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

  NCT05076149· Phase 3· Source

• Completed

  A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

  NCT05033080· Phase 3· Source

• Completed

  Electrical Vestibular Nerve Stimulation (VeNS) Compared to Sham Control As a Means of Improving Glycemic Control in Adults with Type 2 Diabetes Mellitus

  NCT04595968· Source

• Completed

  A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

  NCT04255433· Phase 3· Source

• Completed

  Prevention of Colorectal Cancer Through Multiomics Blood Testing

  NCT04369053· Source

• Completed

  A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)

  NCT04138277· Phase 3· Source

• Completed

  Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

  NCT03500328· Source

• Completed

  A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

  NCT03412565· Phase 2· Source

• Terminated

  Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation

  NCT02928497· Source

• Completed

  Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile

  NCT01454297· Source